Skip to main
CORT
CORT logo

Corcept Therapeutics (CORT) Stock Forecast & Price Target

Corcept Therapeutics (CORT) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Corcept Therapeutics Inc. is poised for a strong financial performance, with annual Korlym sales projected to grow by 19% to 26% year-over-year, reflecting robust underlying demand and a significant increase in volume over the past two quarters. The potential expansion of relacorilant into additional cancer indications, bolstered by promising clinical trial results, indicates a substantial growth trajectory for the company's product pipeline. Furthermore, the anticipated growth of the Cushing’s syndrome market and the capacity improvement over time could contribute to the franchise evolving into a multi-billion dollar market segment within the next five years.

Bears say

Corcept Therapeutics is facing potential near-term earnings headwinds, particularly with expected downward revisions to its 2025 revenue guidance, which is projected to fall to $824 million, below the current guidance range of $850 million to $900 million. The company has lowered its sales forecast for Korlym by approximately 10% for the latter half of 2025, reflecting ongoing challenges related to commercial distribution and supply chain issues. Furthermore, the departure of Optime might indicate underlying instability within the management strategy, contributing to a cautious outlook on the company's financial performance moving forward.

Corcept Therapeutics (CORT) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Corcept Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Corcept Therapeutics (CORT) Forecast

Analysts have given Corcept Therapeutics (CORT) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Corcept Therapeutics (CORT) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $139, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $139, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Corcept Therapeutics (CORT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.